Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
暂无分享，去创建一个
[1] P. Elkin,et al. Body mass index (BMI) Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] R. Rosell,et al. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[3] Qi Zhou,et al. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial , 2019, Clinical Cancer Research.
[4] A. Cardona,et al. Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer , 2016, BMC Cancer.
[5] R. Perez-Padilla,et al. [National consensus of diagnosis and treatment of non-small cell lung cancer]. , 2013, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.